PBYI Stock — Puma Biotechnology Inc: Cash, EV, Pipeline

Share price

$9.60

Market cap

$495.6M

Cash

$93.9M

Enterprise value

$401.7M

Balance sheet

Cash	$93.9M
Debt	$0.0M
Net cash	$93.9M
Enterprise value	$401.7M
Basic shares	51.1M shares
Fully diluted shares	59.5M shares
Fully diluted market cap	$571.0M
Cash per share	$1.84

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading PBYI daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Dec 11, 2027 - Jan 22, 2028	Alisertib	Phase 2	Small Cell Lung Cancer	—
Feb 10 - Mar 23	Alisertib	Phase 2	Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer	—
Mar 14 - Apr 25	Temozolomide	Phase 2	Glioblastoma	—
May 12 - Jun 23	Alisertib	Phase 2	Small Cell Lung Cancer ( SCLC )	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Neratinib

Approved · Active Modality: small molecule (oral)

Aliases PB272

Target HER2

Partnerships Ex-US sub-licensees: commercialization and regulatory approval efforts outside the US

Indications

early-stage HER2-positive breast cancer (extended adjuvant) (Approved)
advanced/metastatic HER2-positive breast cancer (Approved)

Status note Marketed as NERLYNX: FDA-approved July 2017 for extended adjuvant treatment of early-stage HER2-overexpressed/amplified breast cancer following trastuzumab; February 2020 for advanced/metastatic HER2-positive breast cancer (with capecitabine); EC authorization 2018. Ongoing Phase 1 trial (NCT05372614, NCI-sponsored) of neratinib with fam-trastuzumab deruxtecan (ENHERTU).

Alisertib

Phase 2 · Active Modality: small molecule (oral)

Target Aurora Kinase A

Partnerships Takeda: exclusive worldwide license for research, development and commercialization ($7M upfront October 2022; up to $287.3M milestones; tiered royalties)

Indications

extensive-stage small cell lung cancer (ALISCA-Lung1) (Phase 2)
breast cancer (ALISCA-Breast1) (Phase 2)

Status note Selective, reversible, ATP-competitive Aurora Kinase A inhibitor. ALISCA-Lung1 Phase 2 (monotherapy, extensive-stage SCLC) initiated February 2024; ALISCA-Breast1 Phase 2 initiated November 2024. Company intends to pursue alisertib initially in SCLC and hormone receptor-positive breast cancer.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Alisertib
Lead indication	Small Cell Lung Cancer
Lead phase	Phase 2
Active trials	3
Collaborator trials	8

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06095505	Phase 2	Recruiting	Sponsor	PBYI	—	Small Cell Lung Cancer	—
NCT06369285	Phase 2	Recruiting	Sponsor	PBYI	—	Hormone Receptor Positive HER-2 Negative Breast Cancer; Metastatic Breast Cancer; Recurrent Breast Cancer	—
NCT07465757	Phase 2	Recruiting	Sponsor	PBYI	—	Small Cell Lung Cancer ( SCLC )	—
NCT03377387	Phase 2	Active, not recruiting	Collaborator	Memorial Sloan Kettering Cancer Center	—	Breast Cancer	—
NCT04886531	Phase 2	Recruiting	Collaborator	Ruth O'Regan	—	Breast Cancer; HER2-positive Breast Cancer; ER Positive Breast Cancer	—
NCT02977780	Phase 2	Recruiting	Collaborator	David Reardon, MD	LLY	Glioblastoma	—
NCT06109467	Phase 2	Active, not recruiting	Collaborator	H. Lee Moffitt Cancer Center and Research Institute	—	GastroEsophageal Cancer; Gastric Cancer	—
NCT05919108	Phase 2	Recruiting	Collaborator	Vanderbilt-Ingram Cancer Center	—	Anatomic Stage I Breast Cancer; Anatomic Stage II Breast Cancer; Anatomic Stage III Breast Cancer	—
NCT05252988	Phase 2	Active, not recruiting	Collaborator	Spanish Breast Cancer Research Group	—	Early-stage Breast Cancer; HER2 Positive Breast Cancer; Hormone Receptor Positive	—
NCT04502602	Phase 1	Active, not recruiting	Collaborator	Virginia Commonwealth University	GSK	Advanced Solid Tumor; Ovarian Cancer	—
NCT05274048	Phase 1	Recruiting	Collaborator	Fox Chase Cancer Center	—	Gastric Cancer; Gastrointestinal Cancer; HER2 Gene Mutation	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 8 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 11 active trials for Puma Biotechnology, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

PBYI — Puma Biotechnology Inc